Cencora Valuation Multiples

Cencora is valued at $63B as of October 2026, a 0.2x revenue multiple. In the last 12 months, Cencora revenue was $338B and Cencora EBITDA was $5.4B.

Cencora Overview

About Cencora

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.


Founded

2001

HQ

United States

Employees

51.0K

Financials (LTM)

Revenue: $338B
EBITDA: $5.4B

EV

$72B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cencora Financials

Cencora reported last 12-month revenue of $338B and EBITDA of $5.4B.

In the same LTM period, Cencora generated $13B in gross profit, $5.4B in EBITDA, and $3.5B in net income.

Revenue (LTM)


Cencora P&L

In the most recent fiscal year, Cencora reported revenue of $321B and EBITDA of $3.6B.

Cencora is profitable as of last fiscal year, with gross margin of 4%, EBITDA margin of 1%, and net margin of 0%.

See analyst estimates for Cencora
LTMLast FY202320242025202620272028
Revenue$338B$321B$270B$301B$325B
Gross Profit$13B$11B$9.2B$10B$12B
Gross Margin4%4%3%3%4%
EBITDA$5.4B$3.6B$3.3B$3.4B$4.1B
EBITDA Margin2%1%1%1%1%
EBIT Margin1%1%1%1%1%
Net Profit$3.5B$1.6B$1.7B$1.5B$2B
Net Margin1%0%1%1%1%
Net Debt-$3.3B---

Financial data powered by Morningstar, Inc.

Cencora Stock Performance

Cencora has current market cap of $63B, and enterprise value of $72B.

Market Cap Evolution


Cencora's stock price is $330.84.

Cencora share price increased by 10.2% in the last 30 days, and decreased by 2.0% in the last year.

Cencora has an EPS (earnings per share) of $8.14.

See more trading valuation data for Cencora
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$72B$63B0.1%10.2%4.2%-2.0%$8.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cencora Valuation Multiples

Cencora trades at 0.2x EV/Revenue multiple, and 13.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Cencora

EV / Revenue (LTM)


Cencora Financial Valuation Multiples

As of October 31, 2026, Cencora has market cap of $63B and EV of $72B.

Cencora has a P/E ratio of 18.1x.

LTMLast FY202320242025202620272028
EV/Revenue0.2x0.2x0.3x0.2x0.2x
EV/EBITDA13.3x20.0x21.6x21.5x17.8x
EV/EBIT15.0x18.4x25.8x21.6x17.4x
EV/Gross Profit5.4x6.3x7.9x7.0x6.1x
P/E18.1x40.6x37.4x41.5x31.0x
EV/FCF25.4x22.5x21.6x23.7x23.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cencora Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cencora Margins & Growth Rates

Cencora grew revenue by 5% and EBITDA by 48% in the last fiscal year.

In the most recent fiscal year, Cencora reported gross margin of 4%, EBITDA margin of 1%, and net margin of 0%.

See estimated margins and future growth rates for Cencora

Cencora Margins

Last FY202420252026202720282029
Gross Margin4%3%4%4%
EBITDA Margin1%1%1%2%
EBIT Margin1%1%1%1%
Net Margin0%1%1%1%
FCF Margin1%1%1%1%

Cencora Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%11%8%5%
Gross Profit Growth15%12%16%12%
EBITDA Growth48%0%21%35%
EBIT Growth22%20%24%17%
Net Profit Growth124%(10%)34%74%
FCF Growth(13%)(9%)2%(4%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Cencora Operational KPIs

Cencora's revenue per employee in the last FY averaged $6.3M, while opex per employee averaged $0.1M for the same period.

Cencora's Rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cencora's Rule of X is 14% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cencora
LTMLast FY202320242025202620272028
Rule of 406%6%---
Bessemer Rule of X13%14%---
Revenue per Employee-$6.3M---
Opex per Employee-$0.1M---
Opex to Revenue-2%2%2%2%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cencora Competitors

Cencora competitors include Grainger, Fastenal, Cardinal Health, Rheinmetall, Sumitomo, Ferguson, Sysco, US Foods, Bunge and Parker Hannifin.

Most Cencora public comparables operate across Wholesale Distribution.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Grainger$18B$2.8B3.7x3.4x24.1x20.0x
Fastenal$8.2B$1.8B7.3x6.5x32.6x28.9x
Cardinal Health$254B$3.5B0.2x0.2x17.9x14.4x
Rheinmetall$11B$2.4B5.3x3.9x24.0x17.3x
Sumitomo$47B$6.1B1.6x1.5x12.5x17.4x
Ferguson$31B$3B1.7x1.6x17.6x15.5x
Sysco$85B$4.1B0.6x0.6x13.1x11.9x
US Foods$39B$1.7B0.7x0.7x16.7x13.2x

This data is available for Pro users. Sign up to see all Cencora competitors and their valuation data.

Start Free Trial

Acquisitions by Cencora

Cencora has acquired 11 companies to date.

Last acquisition by Cencora was on October 21st 2026. Cencora acquired American Oncology Network for $2.4B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Cencora

American Oncology Network
EyeSouth (retina unit)
OneOncology
NextPharma Logistics
Description
American Oncology Network is a US community oncology management services organization headquartered in Fort Myers, Florida, founded in 2018. It partners with independent oncology practices and physicians, who keep control of treatment decisions while the network supplies shared administrative, technology and clinical infrastructure. Its service lines include specialty and infusion pharmacy, pathology and laboratory services, radiation and radiology, clinical trials, care coordination and value-based care programmes. Practices join to gain scale, purchasing power and access to ancillary services that generate additional revenue within the practice. The network earns income from patient services delivered by affiliated physicians and from pharmacy, laboratory and other ancillary services, and from management fees. It operates across many US states and became a public company traded over the counter. Its patients are cancer patients treated by affiliated practices, and its direct partners are physician groups.
EyeSouth (retina unit) runs a network of physician-led ophthalmology practices treating retinal conditions like macular degeneration and diabetic retinopathy. Specialists provide diagnostic imaging, surgery, and monitoring, supported by shared billing, compliance, and operations. Network practices access clinical trials and advanced therapies.
-
NextPharma Logistics is a temperature-controlled logistics provider for pharmaceuticals, handling warehousing, order fulfillment, project distribution, and returns management. Its GDP-compliant facilities in Europe store products from 2-8°C to 15-25°C with real-time tracking via SAP. Monthey-headquartered in Switzerland, it supports clinical trials and commercial supply chains for clients like Roche.
HQ CountryUnited States-United StatesGermany
HQ City
Fort Myers
-
-
Bielefeld
Deal Date21 Oct 202622 Mar 202615 Dec 202512 Oct 2025
Valuation$2.4B$1.1B$7.4Bundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cencora acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Cencora

Cencora has invested in 2 companies to date.

Latest investment by Cencora was on September 13th 2023. Cencora invested in Sempre Health in their $20M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Cencora

Sempre Health
WhizAI
WhizAI
Description
Sempre Health is a healthcare technology company introducing dynamic pricing for prescriptions nationwide. By analyzing millions of records to predict patient behaviors, it sends personalized price offers via text to pharmacies, lowering costs, extending affordability, and improving outcomes while building datasets on price sensitivities.
-
-
HQ CountryUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Somerset, NJ
Somerset, NJ
Deal Date13 Sep 202325 Oct 202214 Dec 2021
RoundSeries CSeries ASeries A
Raised$20M$6M$8M
InvestorsIndustry Ventures; The Blue Venture Fund; Cencora; UPMC Enterprises; Echo Health VenturesCencora; Vertical Venture Partners; Shanda Group; Healthy VenturesCencora; Vertical Venture Partners; Shanda Group
Valuationundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cencora investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cencora

When was Cencora founded?Cencora was founded in 2001.
Where is Cencora headquartered?Cencora is headquartered in United States.
How many employees does Cencora have?As of today, Cencora has over 51K employees.
Who is the CEO of Cencora?Cencora's CEO is Robert P. Mauch.
Is Cencora publicly listed?Yes, Cencora is a public company listed on NYSE.
What is the stock symbol of Cencora?Cencora trades under COR ticker.
When did Cencora go public?Cencora went public in 1995.
Who are competitors of Cencora?Cencora main competitors include Grainger, Fastenal, Cardinal Health, Rheinmetall, Sumitomo, Ferguson, Sysco, US Foods, Bunge, Parker Hannifin.
What is the current market cap of Cencora?Cencora's current market cap is $63B.
What is the current revenue of Cencora?Cencora's last 12 months revenue is $338B.
What is the current revenue growth of Cencora?Cencora revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Cencora?Current revenue multiple of Cencora is 0.2x.
What is the current EBITDA of Cencora?Cencora's last 12 months EBITDA is $5.4B.
What is Cencora's EBITDA margin?Cencora's last 12 months EBITDA margin is 2%.
What is the current EV/EBITDA multiple of Cencora?Current EBITDA multiple of Cencora is 13.3x.
What is the current FCF of Cencora?Cencora's last 12 months FCF is $2.8B.
What is Cencora's FCF margin?Cencora's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of Cencora?Current FCF multiple of Cencora is 25.4x.
How many companies Cencora has acquired to date?As of October 2026, Cencora has acquired 11 companies.
What was the largest acquisition by Cencora?$7.4B acquisition of OneOncology on 15th December 2025 was the largest M&A Cencora has done to date.
What companies Cencora acquired?Cencora acquired OneOncology, Alliance Healthcare, Retina Consultants of America, PharMEDium Healthcare, MWI Veterinary Supply, American Oncology Network, PharmaLex, EyeSouth (retina unit), H. D. Smith, St. Francis Group, and 1 other company.
In how many companies Cencora has invested to date?As of October 2026, Cencora has invested in 2 companies.
What was the last Cencora investment?On 13th September 2023 Cencora invested in Sempre Health, participating in a $20M Series C round, alongside Industry Ventures, The Blue Venture Fund, UPMC Enterprises, and Echo Health Ventures.
In what companies Cencora invested in?Cencora invested in Sempre Health and WhizAI.

See public comps similar to Cencora

Lists including Cencora

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial